July 7, 2008 - ImmunoGen, Inc. (Nasdaq: IMGN) announced the start of patient dosing in a Phase I clinical trial evaluating the Company's IMGN388 targeted anticancer compound for the treatment of solid tumors. IMGN388 uses ImmunoGen's Tumor-Activated Prodrug (TAP) technology with an antibody that binds to an integrin target. ImmunoGen submitted the Investigational New Drug (IND) application for IMGN388 to the US Food and Drug Administration in mid-May 2008 and gained authorization to initiate clinical testing in mid-June 2008...
... IMGN388 consists of the Company's DM4 cell-killing agent attached to an antibody that binds specifically to an integrin expressed on a wide range of solid tumors - melanomas, sarcomas and many carcinomas, including lung, bladder, renal cell and thyroid carcinomas... ImmunoGen's Press Release -
Blog Archive
-
▼
2008
(297)
-
▼
July
(29)
- Lorus Therapeutics : Allowance of New United State...
- Curis : Hsp90 Inhibitor CUDC-305 as Development Ca...
- AngioDynamics : Radiofrequency Ablation Yields Hig...
- ImmunoGen : Start of IMGN388 Clinical Testing
- Resolvyx Pharmaceuticals : First In-Vivo Data Sho...
- Illumina Infinium High-Density (HD) DNA Analysis P...
- Talecris Biotherapeutics : Orphan Drug Designation...
- FoldRx : Novel Therapeutic Approach for Treating C...
- Emergent BioSolutions and the University of Oxford...
- Nabi Biopharmaceuticals : Positive Interim Results...
- OSI Pharmaceuticals : Clinical Development Program...
- Threshold Pharmaceuticals : Interim Results From a...
- Genentech : Receipt of Proposal From Roche
- Alfacell : Novel Combination of Alfacell's ONCONAS...
- Luminex and ViroNovative : License Agreement for H...
- Schering-Plough and Merck & Co. : Withdrawal of L...
- RegeneRx : First Patent on TB4's Ability to Repair...
- BioNumerik Pharmaceuticals : Evidence of a Surviva...
- Advanced Life Sciences : Collaboration With UK Min...
- Genzyme Corporation and PTC Therapeutics : Collabo...
- Cyclacel : study of seliciclib synergy with Tarcev...
- Theravance : Clinical Results in the LAMA Respirat...
- Mpex : Phase 2 Clinical Trial of Aerosol MP-376 in...
- Aradigm : Phase 2 Data with Inhaled Liposomal Cipr...
- Novartis : strategic partnership with Lonza to acc...
- Znomics Launches Drug Discovery Program for Treatm...
- Icagen : Phase I Multiple Ascending Dose Clinical ...
- Micromet and Nycomed : Formal Preclinical Safety S...
- Cell Therapeutics : Complete Study Results Compari...
-
▼
July
(29)